Industry Trends

Ozempic now available in India

Ozempic, a once-weekly injectable formulation of semaglutide—is approved in India for adults with type 2 diabetes as the first line treatment, adjunct to diet and exercise

Industry Trends

India’s AI royalty plan ‘not sustainable’, likely to fail in implementation: Quantum Hub’s Rohit Kumar

India’s ambitious push to establish a compulsory royalty system for AI training data is drawing early scepticism from policy circles. Experts warn that the global-revenue-based fee structure and the proposed blanket licensing regime could create operational bottlenecks, diminish creator autonomy, and complicate commercial deployment for AI companies. As consultations begin, the debate is shifting from principle to practicality — and whether the framework can be meaningfully implemented at scale.

Industry Trends

BEL wins fresh orders worth ₹776 crore for next-gen defence systems

BEL has been steadily building its order pipeline through the year, supported by continued demand for network-centric systems, advanced communication platforms, and next-generation surveillance and combat solutions. Shares of BEL ended 0.5% higher at ₹389.45 on the NSE today, December 12.